272 related articles for article (PubMed ID: 19883640)
1. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Xu X; Zhang L; Liang J
Mol Med Rep; 2013 Aug; 8(2):385-92. PubMed ID: 23799547
[TBL] [Abstract][Full Text] [Related]
4. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
Custodis F; Eberl M; Kilter H; Böhm M; Laufs U
Cardiovasc Res; 2006 Jul; 71(2):342-51. PubMed ID: 16698001
[TBL] [Abstract][Full Text] [Related]
5. G(alphaq)-protein carboxyl terminus imitation polypeptide GCIP-27 attenuates cardiac hypertrophy in vitro and in vivo.
Zhang HG; Li XH; Zhou JZ; Liu Y; Jia Y; Yuan ZB
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1276-81. PubMed ID: 17973867
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
Irukayama-Tomobe Y; Miyauchi T; Sakai S; Kasuya Y; Ogata T; Takanashi M; Iemitsu M; Sudo T; Goto K; Yamaguchi I
Circulation; 2004 Feb; 109(7):904-10. PubMed ID: 14967736
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
8. The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes.
Barac YD; Zeevi-Levin N; Yaniv G; Reiter I; Milman F; Shilkrut M; Coleman R; Abassi Z; Binah O
Cardiovasc Res; 2005 Oct; 68(1):75-86. PubMed ID: 16005448
[TBL] [Abstract][Full Text] [Related]
9. Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes.
Singal T; Dhalla NS; Tappia PS
J Mol Cell Cardiol; 2006 Jul; 41(1):126-37. PubMed ID: 16714034
[TBL] [Abstract][Full Text] [Related]
10. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
11. Role of mitogen-activated protein kinase pathway in reactive oxygen species-mediated endothelin-1-induced beta-myosin heavy chain gene expression and cardiomyocyte hypertrophy.
Cheng TH; Shih NL; Chen CH; Lin H; Liu JC; Chao HH; Liou JY; Chen YL; Tsai HW; Chen YS; Cheng CF; Chen JJ
J Biomed Sci; 2005; 12(1):123-33. PubMed ID: 15864745
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes.
Li H; Shi S; Sun YH; Zhao YJ; Li QF; Li HZ; Wang R; Xu CQ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):312-8. PubMed ID: 18986329
[TBL] [Abstract][Full Text] [Related]
13. Contractile arrest reveals calcium-dependent stimulation of SERCA2a mRNA expression in cultured ventricular cardiomyocytes.
Vlasblom R; Muller A; Musters RJ; Zuidwijk MJ; Van Hardeveld C; Paulus WJ; Simonides WS
Cardiovasc Res; 2004 Aug; 63(3):537-44. PubMed ID: 15276479
[TBL] [Abstract][Full Text] [Related]
14. DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities.
Lu YM; Shioda N; Han F; Kamata A; Shirasaki Y; Qin ZH; Fukunaga K
Cardiovasc Ther; 2009; 27(1):17-27. PubMed ID: 19207476
[TBL] [Abstract][Full Text] [Related]
15. A farnesyltransferase inhibitor attenuates cardiac myocyte hypertrophy and gene expression.
Calderone A; Abdelaziz N; Colombo F; Schreiber KL; Rindt H
J Mol Cell Cardiol; 2000 Jun; 32(6):1127-40. PubMed ID: 10888263
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy.
Kim YK; Suarez J; Hu Y; McDonough PM; Boer C; Dix DJ; Dillmann WH
Circulation; 2006 Jun; 113(22):2589-97. PubMed ID: 16735677
[TBL] [Abstract][Full Text] [Related]
17. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
Laufs U; Kilter H; Konkol C; Wassmann S; Böhm M; Nickenig G
Cardiovasc Res; 2002 Mar; 53(4):911-20. PubMed ID: 11922901
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells.
Kim YS; Ahn Y; Hong MH; Kim KH; Park HW; Hong YJ; Kim JH; Kim W; Jeong MH; Cho JG; Park JC; Kang JC
J Cardiovasc Pharmacol; 2007 Jun; 49(6):376-83. PubMed ID: 17577102
[TBL] [Abstract][Full Text] [Related]
19. PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes.
Pan J; Singh US; Takahashi T; Oka Y; Palm-Leis A; Herbelin BS; Baker KM
J Cell Physiol; 2005 Feb; 202(2):536-53. PubMed ID: 15316932
[TBL] [Abstract][Full Text] [Related]
20. [Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A].
Zhou DX; Liang QS; He XX; Zhan CY
Zhongguo Zhong Yao Za Zhi; 2008 Apr; 33(8):936-9. PubMed ID: 18619357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
